The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Observational · No treatment assigned · 1 site · University of Chicago
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Patients Undergoing Routine Health Care, Heart Diseases and Inflammatory Bowel Diseases. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
- Life expectancy of at least 3 years
- Must be 18 years or older
Plus 8 more requirement(s). There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 1200 participants are expected to take part.
- Start date: 2011-01-14.
- Main results expected around 2027-11-14 (estimate from the record).
- 1 study site listed (1 marked recruiting) in United States.
Main thing being measured
- Feasibility of incorporating pharmacogenomic testing into routine medical care (5 years)
In the researchers’ words
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Patients Undergoing Routine Health Care; Heart Diseases; Inflammatory Bowel Diseases; Autoimmune Disease; Inflammatory Disease; Blood Coagulation Disorders; Hepatitis C; Non-Metastatic Neoplasm |
| Lead sponsor | University of Chicago |
| Enrollment | 1200 (estimated) |
| Start date | 2011-01-14 |
| Primary completion (est.) | 2027-11-14 |
| First posted | 2011-01-21 |
| Last updated | 2026-03-04 |
| Official title | The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing |
| ClinicalTrials.gov ID | NCT01280825 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial * Life expectancy of at least 3 years * Must be 18 years or older * Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years * Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to: * Patients requiring specialized cardiology care * Patients with inflammatory bowel diseases * Patients with systemic autoimmune or inflammatory diseases * Patients requiring long-term oral anticoagulation * Patients with hepatitis C * Patients with non-metastatic cancer Exclusion Criteria: * Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years. * Patients who have undergone, or are being actively considered for, liver or kidney transplantation. * Inability to understand and give informed consent to participate.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Medical Center | Chicago, Illinois | United States | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.